Kezar Life Sciences (NASDAQ:KZR) Trading 3.1% Higher

Kezar Life Sciences, Inc. (NASDAQ:KZR) shares were up 3.1% on Tuesday . The stock traded as high as $0.85 and last traded at $0.84. Approximately 452,675 shares were traded during trading, a decline of 34% from the average daily volume of 681,233 shares. The stock had previously closed at $0.81.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Kezar Life Sciences in a research note on Friday, March 15th.

Kezar Life Sciences Price Performance

The stock’s 50-day moving average price is $0.88 and its 200 day moving average price is $0.87. The company has a quick ratio of 11.66, a current ratio of 11.66 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $61.15 million, a price-to-earnings ratio of -0.60 and a beta of 0.47.

Kezar Life Sciences (NASDAQ:KZR) last issued its earnings results on Thursday, March 14th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.04. Equities research analysts expect that Kezar Life Sciences, Inc. will post -1.26 earnings per share for the current fiscal year.

Institutional Trading of Kezar Life Sciences

Several institutional investors have recently made changes to their positions in the company. Fidelis Capital Partners LLC purchased a new stake in Kezar Life Sciences in the 1st quarter valued at about $25,000. SG Americas Securities LLC acquired a new position in shares of Kezar Life Sciences in the 3rd quarter worth approximately $39,000. Pale Fire Capital SE purchased a new position in shares of Kezar Life Sciences during the 3rd quarter worth approximately $82,000. Panagora Asset Management Inc. acquired a new stake in Kezar Life Sciences in the 4th quarter valued at approximately $80,000. Finally, Marquette Asset Management LLC purchased a new stake in Kezar Life Sciences in the first quarter valued at approximately $114,000. Hedge funds and other institutional investors own 67.90% of the company’s stock.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.